Amarin Corporation

Summary
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

History

Amarin Corporation plc was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.


Mission
Amarin's mission is to create and commercialize innovative therapeutics to help prevent and treat cardiovascular and metabolic diseases, improve patient outcomes and address unmet medical needs.

Vision
Amarin's vision is to be the global leader in nanovector-based cardiovascular and metabolic therapeutics, revolutionizing the way people think about and treat cardiovascular and metabolic disease.

Key Team

Mr. Aaron D. Berg (Exec. VP & Pres of U.S.)

Mr. Thomas Charles Reilly (CFO & Sr. VP)

Dr. David Keenan (Sr. VP of Technical Operations)

Ms. Lisa M. DeFrancesco (Sr. VP of Corp. Affairs & Investor Relations)

Alina Kolomeyer (Director of Communications)

Mr. Jordan Zwick (Sr. VP of Corp. Bus. Devel.)

Ms. Donna Pasek (Sr. VP of HR)


Recognition and Awards
Amarin has won numerous awards for its successful research accomplishments in cardiovascular health and metabolic health, including the PROSE Award in Medical Science, the Outstanding Scientific Achievement Award from the American Heart Association, and the Inaugural Award for Excellence in Research from the American College of Cardiology.

References
Amarin Corporation
Leadership team

Mr. Karim Mikhail (Pres, CEO & Director)

Dr. Steven B. Ketchum Ph.D. (Pres of R&D, Exec. VP and Chief Scientific Officer)

Mr. Joseph T. Kennedy J.D. (Exec. VP of Strategic Initiatives & Gen. Counsel)

Products/ Services
Biopharma, Biotechnology, Health Care, Pharmaceutical
Number of Employees
500 - 1000
Headquarters
Ballsbridge, Dublin, Ireland
Established
1991
Company Registration
SEC CIK number: 0000897448
Revenue
100M - 500M
Traded as
AMRN
Social Media
Sun Mar 03 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium